Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | GRM5 | P41594 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4856775 | 0.91 | F10 (0.55) | F10NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL4855305 | 0.89 | F10 (0.64) | F10NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL4856391 | 0.89 | F10 (0.63) | F10KDM4EALDH1A1HSD17B10KCNH2 | |
| SCHEMBL4860120 | 0.89 | NPC1 (0.57) | F10NPC1RAB9AGRM5KDM4E | |
| SCHEMBL4851596 | 0.88 | F10 (0.63) | F10NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL4856406 | 0.85 | F10 (0.64) | F10NPC1RAB9AALDH1A1KCNH2 | |
| SCHEMBL4854352 | 0.85 | F10 (0.63) | F10NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4858193 | 0.84 | F10 (0.64) | F10NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL4855264 | 0.82 | F10 (0.56) | F10NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL4858178 | 0.81 | F10 (0.57) | F10NPC1RAB9AGRM5SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449457-B2 | Substituted heterocyclic carboxamides with antithrombotic activity | ELI LILLY AND COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449457-B2 | Substituted heterocyclic carboxamides with antithrombotic activity | ELI LILLY AND COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449457-B2 | Substituted heterocyclic carboxamides with antithrombotic activity | ELI LILLY AND COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1307444-B1 | SUBSTITUTED HETEROCYCLIC AMIDES | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7160878-B2 | Substituted heterocyclic amides | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160878-B2 | Substituted heterocyclic amides | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160878-B2 | Substituted heterocyclic amides | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-20040242581-A1 | Substituted heterocyclic carboxamides with antithrombotic activity | ELI LILLY AND COMPANY | 2004-12-02 | — | — | US | disclosed |
| EP-1456175-A1 | SUBSTITUTED HETEROCYCLIC CARBOXAMIDES WITH ANTITHROMBOTIC ACTIVITY | ELI LILLY AND COMPANY (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20040097491-A1 | Substituted heterocyclic amides | HERRON DAVID KENT (US) | 2004-05-20 | — | — | US | disclosed |
| WO-2003050088-A1 | SUBSTITUTED HETEROCYCLIC CARBOXAMIDES WITH ANTITHROMBOTIC ACTIVITY | ELI LILLY AND COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003050088-A1 | SUBSTITUTED HETEROCYCLIC CARBOXAMIDES WITH ANTITHROMBOTIC ACTIVITY | ELI LILLY AND COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| EP-1307444-A2 | SUBSTITUTED HETEROCYCLIC AMIDES | ELI LILLY AND COMPANY (US) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002010154-A2 | SUBSTITUTED HETEROCYCLIC AMIDES | ELI LILLY AND COMPANY (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242581-A1 | Substituted heterocyclic carboxamides with antithrombotic activity | F11, SERPINC1, TFPI | F10 15/4885NPC1 2571/4885RAB9A 3682/4885 |
| US-20040097491-A1 | Substituted heterocyclic amides | F12, F11, F8 | F10 11/4885NPC1 2192/4885RAB9A 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.